GLP‑1 responses tied to genetics

These drugs work by copying a gut hormone called glucagon-like peptide 1, which tells the brain you’ve eaten and slows how fast food leaves the stomach. Semaglutide, sold as Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro, use that pathway to lower appetite and body weight. (nature.com) The puzzle is that two people can take the same weekly shot and get very different results. Doctors have seen big gaps in weight loss and in stomach side effects like nausea and vomiting, but they have not had a clear biological reason for that spread. (reuters.com) A gene is the body’s instruction manual, and a genetic variant is a one-letter edit in that manual. Researchers asked whether some of those edits change how strongly a person responds when a glucagon-like peptide 1 drug presses on the same appetite-control system. (nature.com) To test that, the 23andMe Research Institute ran a genome-wide association study, which is a scan across the whole genome looking for recurring DNA differences linked to an outcome. The team analyzed self-reported treatment data from 27,885 people who had used a glucagon-like peptide 1 receptor agonist. (nature.com) The clearest weight-loss signal showed up in GLP1R, the gene that builds the receptor these drugs target. One missense variant in GLP1R was tied to about 0.76 kilograms of extra weight loss per copy of the effect allele, meaning the drug’s target itself seems to change how much benefit some people get. (nature.com) The clearest side-effect signal showed up in GIPR, a different receptor gene involved in the same hormone network. A variant there was linked to higher odds of nausea and vomiting, especially in people using tirzepatide, which hits both the glucose-dependent insulinotropic polypeptide pathway and the glucagon-like peptide 1 pathway. (nature.com) That split matters because semaglutide mainly targets glucagon-like peptide 1, while tirzepatide targets glucagon-like peptide 1 plus glucose-dependent insulinotropic polypeptide. The study suggests that when a drug acts on more than one hormone signal, different genes can shape side effects in different ways. (nature.com) The researchers did not say DNA is destiny. Their model worked best when genetic markers were combined with age, sex, body size, and clinical history, which means genes explain part of the variation rather than all of it. (23andme.com) This also was not a randomized clinical trial with measured weights in a clinic. The Nature paper used self-reported outcomes from 23andMe participants, so the findings are strongest as a map of likely biological differences, not as a prescription rule doctors can use tomorrow. (nature.com) What changed this week is that the “some people just respond differently” story got pinned to specific genes in a dataset large enough to see the pattern. Reuters reported the work on April 10, 2026, and the paper was published in Nature on April 8, 2026, which puts personalized prescribing of these drugs a step closer to something measurable. (reuters.com)